|Other Names||CD9 antigen, 5H9 antigen, Cell growth-inhibiting gene 2 protein, Leukocyte antigen MIC3, Motility-related protein, MRP-1, Tetraspanin-29, Tspan-29, p24, CD9, CD9, MIC3, TSPAN29|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP1482a was selected from the N-term region of human CD9. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Involved in platelet activation and aggregation. Regulates paranodal junction formation. Involved in cell adhesion, cell motility and tumor metastasis. Required for sperm-egg fusion.|
|Cellular Location||Membrane; Multi-pass membrane protein. Cell membrane; Multi-pass membrane protein|
|Tissue Location||Detected in platelets (at protein level). Expressed by a variety of hematopoietic and epithelial cells|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
CD9 is a member of the transmembrane 4 superfamily, also known as the tetraspanin family. Most of these members are cell-surface proteins that are characterized by the presence of four hydrophobic domains. The proteins mediate signal transduction events that play a role in the regulation of cell development, activation, growth and motility. This protein is a cell surface glycoprotein that is known to complex with integrins and other transmembrane 4 superfamily proteins. It can modulate cell adhesion and migration and also trigger platelet activation and aggregation. In addition, the protein appears to promote muscle cell fusion and support myotube maintenance.
Ovalle,S., Int. J. Cancer 121 (10), 2140-2152 (2007)Kovalenko,O.V., Mol. Cell Proteomics 6 (11), 1855-1867 (2007)Abache,T., J. Cell. Biochem. 102 (3), 650-664 (2007)Horejsi,V., FEBS Lett. 288 (1-2), 1-4 (1991)
If you have any additional inquiries please email technical services at email@example.com.